Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous umbilical cord blood reinfusion
- Development stage
- Phase 2
- Lead developer
- Duke University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous UCB Reinfusion is an investigational cell therapy involving the intravenous infusion of a pediatric patient's own umbilical cord blood (UCB) stem cells, which include hematopoietic and other progenitor cells collected at birth. Developed primarily by Dr. Joanne Kurtzberg at Duke University's Marcus Center for Cellular Cures, the therapy is investigated for its potential to treat spastic cerebral palsy. The proposed biological mechanism involves the cells' ability to cross the blood-brain barrier, reduce neuroinflammation, and facilitate neural repair and connectivity through paracrine signaling. A randomized, placebo-controlled Phase 2 trial demonstrated that children receiving a dose of at least 25 million cells/kg showed significant improvements in motor function and brain connectivity compared to placebo.
- Other names
- autologous umbilical cord bloodautologous UCBautologous cord blood infusion
Beyond the preview
Go deeper on autologous umbilical cord blood reinfusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous umbilical cord blood reinfusion.